Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma detailed significant progress in Q1 2026, including upcoming FDA and EMA submissions for obexelimab treating IgG4-RD, completion of enrollment in SLE and Phase 1 trials, ongoing Phase 3 trials for orelabrutinib in MS, and a strengthened balance sheet with cash runway into 2029. The company projects multiple clinical and regulatory m…